Cytokinetics (CYTK)
Cytokinetics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
18.6M
Short interest
settlement 2026-10-15
8.7
Days to cover
+0.3 days vs prior
53.5%
Short share of volume
2026-10-28
2,845
Fails to deliver
settlement 2026-09-30
Wed 4 Nov
Next earnings
estimated date
-$11.8M
Insider flow, 90 days
0 buys, 15 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CYTK is 18,628,116 shares, up 1,146,733 shares over the last month. Over the last 48 readings it ranged from 12,948,508 shares (28 November 2025) to 19,333,243 shares (30 September 2026). At the reported average volume of 2.1M shares a day that is 8.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cytk" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 18,628,116 | -3.6% | 2,138,708 | 8.71 |
| 2026-09-30 | 19,333,243 | +10.6% | 2,309,189 | 8.37 |
| 2026-09-15 | 17,481,383 | +0.2% | 1,657,464 | 10.55 |
| 2026-08-31 | 17,442,378 | +6.8% | 1,792,286 | 9.73 |
| 2026-08-14 | 16,323,712 | +6.7% | 2,123,941 | 7.69 |
| 2026-07-31 | 15,303,504 | -10.3% | 1,589,679 | 9.63 |
| 2026-07-15 | 17,051,981 | -3.0% | 1,897,013 | 8.99 |
| 2026-06-30 | 17,573,660 | +19.0% | 3,335,085 | 5.27 |
| 2026-06-15 | 14,766,477 | -4.7% | 1,587,014 | 9.30 |
| 2026-05-29 | 15,500,865 | -5.8% | 1,812,301 | 8.55 |
| 2026-05-15 | 16,461,785 | +3.6% | 4,864,393 | 3.38 |
| 2026-04-30 | 15,896,196 | +6.8% | 1,641,635 | 9.68 |
| 2026-04-15 | 14,885,295 | -6.1% | 1,655,992 | 8.99 |
| 2026-03-31 | 15,848,869 | +1.2% | 2,162,136 | 7.33 |
| 2026-03-13 | 15,662,163 | +1.9% | 1,971,973 | 7.94 |
| 2026-02-27 | 15,367,539 | +4.0% | 1,713,609 | 8.97 |
| 2026-02-13 | 14,783,466 | +11.1% | 1,724,201 | 8.57 |
| 2026-01-30 | 13,308,302 | -0.6% | 1,537,559 | 8.66 |
| 2026-01-15 | 13,391,148 | -3.2% | 2,012,954 | 6.65 |
| 2025-12-31 | 13,837,421 | +3.7% | 2,351,721 | 5.88 |
| 2025-12-15 | 13,341,806 | +3.0% | 1,732,366 | 7.70 |
| 2025-11-28 | 12,948,508 | -10.0% | 1,737,894 | 7.45 |
| 2025-11-14 | 14,382,900 | +4.3% | 1,946,832 | 7.39 |
| 2025-10-31 | 13,786,011 | -2.9% | 1,702,901 | 8.10 |
| 2025-10-15 | 14,198,078 | +0.6% | 1,913,024 | 7.42 |
| 2025-09-30 | 14,111,890 | -1.0% | 2,898,854 | 4.87 |
| 2025-09-15 | 14,257,043 | +3.1% | 3,630,662 | 3.93 |
| 2025-08-29 | 13,832,481 | -9.7% | 1,759,783 | 7.86 |
| 2025-08-15 | 15,325,098 | -1.3% | 1,593,566 | 9.62 |
| 2025-07-31 | 15,520,330 | -2.6% | 1,209,631 | 12.83 |
| 2025-07-15 | 15,929,741 | +6.1% | 1,468,526 | 10.85 |
| 2025-06-30 | 15,020,046 | +7.3% | 1,468,875 | 10.23 |
| 2025-06-13 | 14,005,230 | -3.4% | 1,321,317 | 10.60 |
| 2025-05-30 | 14,498,427 | -7.1% | 1,713,067 | 8.46 |
| 2025-05-15 | 15,602,822 | +7.8% | 3,007,384 | 5.19 |
| 2025-04-30 | 14,480,043 | +3.8% | 1,505,811 | 9.62 |
| 2025-04-15 | 13,947,306 | -2.7% | 2,909,070 | 4.79 |
| 2025-03-31 | 14,333,413 | +0.8% | 1,785,906 | 8.03 |
| 2025-03-14 | 14,220,519 | +1.1% | 1,540,969 | 9.23 |
| 2025-02-28 | 14,072,458 | -6.6% | 1,749,349 | 8.04 |
| 2025-02-14 | 15,069,465 | +10.4% | 2,204,930 | 6.83 |
| 2025-01-31 | 13,653,135 | -2.7% | 1,197,757 | 11.40 |
| 2025-01-15 | 14,030,843 | +2.4% | 1,141,143 | 12.30 |
| 2024-12-31 | 13,706,782 | -0.2% | 1,265,925 | 10.83 |
| 2024-12-13 | 13,730,415 | -2.1% | 985,451 | 13.93 |
| 2024-11-29 | 14,030,531 | -3.8% | 1,350,637 | 10.39 |
| 2024-11-15 | 14,588,795 | -7.0% | 1,451,772 | 10.05 |
| 2024-10-31 | 15,689,835 | +1.0% | 870,265 | 18.03 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of CYTK volume is 53.5%, down 10.7 points over the last five sessions. Over the last 30 readings it ranged from 37.7% (17 September 2026) to 79.4% (29 September 2026). The latest reading is 8.4 points below the 30-session average of 61.9%, on 556K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 298K | 556K | 53.5% | 46 |
| 2026-10-27 | 269K | 487K | 55.3% | 1,049 |
| 2026-10-26 | 162K | 288K | 56.4% | 0 |
| 2026-10-23 | 212K | 438K | 48.4% | 0 |
| 2026-10-22 | 310K | 563K | 55.1% | 582 |
| 2026-10-21 | 282K | 439K | 64.2% | 141 |
| 2026-10-20 | 313K | 425K | 73.7% | 5,080 |
| 2026-10-19 | 486K | 629K | 77.2% | 0 |
| 2026-10-16 | 333K | 475K | 70.1% | 3,748 |
| 2026-10-15 | 403K | 615K | 65.5% | 2,410 |
| 2026-10-14 | 501K | 781K | 64.1% | 3,936 |
| 2026-10-13 | 459K | 733K | 62.6% | 0 |
| 2026-10-12 | 296K | 442K | 66.9% | 3,775 |
| 2026-10-09 | 269K | 393K | 68.5% | 0 |
| 2026-10-08 | 604K | 933K | 64.7% | 1,226 |
| 2026-10-07 | 470K | 1.1M | 41.7% | 8 |
| 2026-10-06 | 702K | 1.3M | 52.8% | 0 |
| 2026-10-05 | 1.0M | 1.5M | 68.5% | 65 |
| 2026-10-02 | 757K | 968K | 78.2% | 2,824 |
| 2026-10-01 | 432K | 738K | 58.6% | 0 |
| 2026-09-30 | 509K | 941K | 54.1% | 20 |
| 2026-09-29 | 803K | 1.0M | 79.4% | 286 |
| 2026-09-28 | 614K | 878K | 69.9% | 0 |
| 2026-09-25 | 583K | 743K | 78.5% | 0 |
| 2026-09-24 | 383K | 635K | 60.2% | 0 |
| 2026-09-23 | 485K | 854K | 56.8% | 0 |
| 2026-09-22 | 650K | 846K | 76.8% | 83,300 |
| 2026-09-21 | 266K | 555K | 47.9% | 150 |
| 2026-09-18 | 262K | 531K | 49.3% | 100 |
| 2026-09-17 | 240K | 637K | 37.7% | 52 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in CYTK is 2,845 shares, down 91,978 shares over the last settlement date. Over the last 30 readings it ranged from 4 shares (11 May 2026) to 2,437,516 shares (8 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 2,845 | $65.64 | $187K |
| 2026-09-22 | 94,823 | $67.56 | $6.4M |
| 2026-09-14 | 98,000 | $73.77 | $7.2M |
| 2026-08-31 | 202 | $72.09 | $15K |
| 2026-08-21 | 60 | $77.18 | $5K |
| 2026-08-12 | 10,465 | $76.45 | $800K |
| 2026-08-11 | 1,196 | $77.49 | $93K |
| 2026-07-23 | 341 | $82.19 | $28K |
| 2026-07-20 | 25,115 | $80.18 | $2.0M |
| 2026-07-16 | 8 | $82.62 | $661 |
| 2026-07-07 | 29 | $85.57 | $2K |
| 2026-07-02 | 142 | $85.26 | $12K |
| 2026-07-01 | 587 | $85.19 | $50K |
| 2026-06-30 | 19,989 | $87.26 | $1.7M |
| 2026-06-29 | 31,203 | $82.19 | $2.6M |
| 2026-06-24 | 2,276 | $80.01 | $182K |
| 2026-06-22 | 17,045 | $78.78 | $1.3M |
| 2026-06-17 | 2,128 | $75.21 | $160K |
| 2026-06-15 | 1,750 | $70.15 | $123K |
| 2026-06-08 | 3,066 | $71.48 | $219K |
| 2026-05-26 | 2,077 | $76.94 | $160K |
| 2026-05-21 | 263,848 | $78.77 | $20.8M |
| 2026-05-20 | 65 | $76.45 | $5K |
| 2026-05-19 | 98 | $75.18 | $7K |
| 2026-05-18 | 355 | $75.85 | $27K |
| 2026-05-15 | 6,306 | $78.64 | $496K |
| 2026-05-14 | 45 | $77.22 | $3K |
| 2026-05-13 | 27,719 | $74.81 | $2.1M |
| 2026-05-11 | 4 | $76.91 | $308 |
| 2026-05-08 | 2,437,516 | $74.29 | $181.1M |
Insider trades
SEC Form 4, newest first. JSONInsiders at CYTK reported 15 open-market sells worth $11.8M in the last 90 days and no open-market buys. Latest filing: Malik Fady Ibraham (EVP Research & Development) on 2026-10-20.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $64.01 | $224K | 154K |
| 2026-10-20 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-10-16 | Wysenski Nancy | Director | Grant | 97 | $63.92 | $6K | 34K |
| 2026-10-16 | Kaye Edward M. MD | Director | Grant | 195 | $63.92 | $12K | 11K |
| 2026-10-16 | Harrington Robert Arthur | Director | Grant | 195 | $63.92 | $12K | 22K |
| 2026-10-16 | Daly James M | Director | Grant | 195 | $63.92 | $12K | 4K |
| 2026-10-16 | WIERENGA WENDELL | Director | Grant | 97 | $63.92 | $6K | 36K |
| 2026-10-16 | HENDERSON JOHN T | Director | Grant | 352 | $63.92 | $22K | 79K |
| 2026-10-12 | Blum Robert I | President & CEO | Sell | 8K | $62.88 | $472K | 279K |
| 2026-10-12 | Blum Robert I | President & CEO | Exercise or conversion | 8K | $10.60 | $80K | 286K |
| 2026-10-06 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $61.38 | $215K | 154K |
| 2026-10-06 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-09-28 | Blum Robert I | President & CEO | Sell | 8K | $65.46 | $491K | 279K |
| 2026-09-28 | Blum Robert I | President & CEO | Exercise or conversion | 8K | $10.60 | $80K | 286K |
| 2026-09-22 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $68.29 | $239K | 154K |
| 2026-09-22 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-09-15 | Blum Robert I | President & CEO | Sell | 98K | $69.33 | $6.8M | 0 |
| 2026-09-15 | Landry Robert E | Director | Sell | 1K | $72.13 | $72K | 8K |
| 2026-09-14 | Blum Robert I | President & CEO | Gift | 98K | $0.00 | $0 | 98K |
| 2026-09-14 | Blum Robert I | President & CEO | Gift | 98K | $0.00 | $0 | 279K |
| 2026-09-14 | Blum Robert I | President & CEO | Gift | 1K | $0.00 | $0 | 376K |
| 2026-09-14 | Blum Robert I | President & CEO | Sell | 8K | $73.44 | $551K | 378K |
| 2026-09-14 | Blum Robert I | President & CEO | Exercise or conversion | 8K | $10.60 | $80K | 385K |
| 2026-09-11 | Landry Robert E | Director | Sell | 1K | $74.66 | $75K | 9K |
| 2026-09-08 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $75.46 | $264K | 154K |
| 2026-09-08 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-09-01 | PARSHALL B LYNNE | Director | Sell | 5K | $71.48 | $357K | 11K |
| 2026-08-31 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 10K | $70.24 | $702K | 59K |
| 2026-08-31 | Callos Andrew | EVP, Chief Commercial Officer | Exercise or conversion | 10K | $23.26 | $233K | 69K |
| 2026-08-31 | Blum Robert I | President & CEO | Sell | 8K | $70.24 | $527K | 378K |
| 2026-08-31 | Blum Robert I | President & CEO | Exercise or conversion | 8K | $10.60 | $80K | 385K |
| 2026-08-18 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $75.82 | $265K | 154K |
| 2026-08-18 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-08-10 | Blum Robert I | President & CEO | Sell | 8K | $76.76 | $576K | 378K |
| 2026-08-10 | Blum Robert I | President & CEO | Exercise or conversion | 8K | $10.60 | $80K | 385K |
| 2026-07-30 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 14K | $79.88 | $1.1M | 59K |
| 2026-07-30 | Callos Andrew | EVP, Chief Commercial Officer | Exercise or conversion | 14K | $23.26 | $326K | 73K |
| 2026-07-27 | Blum Robert I | President & CEO | Sell | 8K | $80.87 | $607K | 378K |
| 2026-07-27 | Blum Robert I | President & CEO | Exercise or conversion | 8K | $10.60 | $80K | 385K |
| 2026-07-21 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $80.59 | $282K | 154K |
| 2026-07-21 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-07-15 | Wysenski Nancy | Director | Grant | 75 | $82.62 | $6K | 34K |
| 2026-07-15 | WIERENGA WENDELL | Director | Grant | 75 | $82.62 | $6K | 36K |
| 2026-07-15 | Kaye Edward M. MD | Director | Grant | 151 | $82.62 | $12K | 10K |
| 2026-07-15 | HENDERSON JOHN T | Director | Grant | 272 | $82.62 | $22K | 78K |
| 2026-07-15 | Harrington Robert Arthur | Director | Grant | 151 | $82.62 | $12K | 22K |
| 2026-07-15 | Daly James M | Director | Grant | 151 | $82.62 | $12K | 3K |
| 2026-07-13 | Blum Robert I | President & CEO | Sell | 7K | $82.02 | $614K | 378K |
| 2026-07-13 | Blum Robert I | President & CEO | Exercise or conversion | 7K | $10.60 | $79K | 385K |
| 2026-07-13 | Blum Robert I | President & CEO | Sell | 10 | $82.02 | $820 | 378K |
| 2026-07-07 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $86.62 | $303K | 154K |
| 2026-07-07 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-07-01 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15K | $85.80 | $1.3M | 59K |
| 2026-07-01 | Callos Andrew | EVP, Chief Commercial Officer | Exercise or conversion | 15K | $23.26 | $349K | 74K |
| 2026-07-01 | Lee Sung | EVP, Chief Financial Officer | Sell | 1K | $87.79 | $98K | 63K |
| 2026-07-01 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 1K | $48.51 | $54K | 64K |
| 2026-07-01 | Blum Robert I | President & CEO | Sell | 8K | $84.92 | $637K | 378K |
| 2026-06-29 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 188 | $44.36 | $8K | 66K |
| 2026-06-29 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 1K | $48.51 | $54K | 65K |
| 2026-06-29 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 823 | $44.36 | $37K | 66K |
| 2026-06-29 | Lee Sung | EVP, Chief Financial Officer | Sell | 3K | $85.00 | $266K | 63K |
| 2026-06-29 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 822 | $44.36 | $36K | 64K |
| 2026-06-29 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 188 | $44.36 | $8K | 63K |
| 2026-06-24 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 1K | $48.51 | $54K | 102K |
| 2026-06-24 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 188 | $44.36 | $8K | 100K |
| 2026-06-24 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 822 | $44.36 | $36K | 101K |
| 2026-06-24 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 1K | $48.51 | $54K | 100K |
| 2026-06-24 | Lee Sung | EVP, Chief Financial Officer | Sell | 39K | $82.30 | $3.2M | 63K |
| 2026-06-24 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 3K | $44.36 | $125K | 99K |
| 2026-06-24 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 9K | $44.36 | $413K | 96K |
| 2026-06-24 | Lee Sung | EVP, Chief Financial Officer | Exercise or conversion | 23K | $48.51 | $1.1M | 87K |
| 2026-06-23 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-06-23 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $79.51 | $278K | 154K |
| 2026-06-15 | Blum Robert I | President & CEO | Sell | 8K | $70.46 | $528K | 385K |
| 2026-06-09 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $67.98 | $238K | 154K |
| 2026-06-09 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-06-01 | Kaye Edward M. MD | Director | Sell | 3K | $76.09 | $223K | 10K |
| 2026-06-01 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15K | $74.08 | $1.1M | 59K |
| 2026-06-01 | Callos Andrew | EVP, Chief Commercial Officer | Exercise or conversion | 15K | $23.26 | $349K | 74K |
| 2026-06-01 | PARSHALL B LYNNE | Director | Sell | 5K | $74.08 | $370K | 16K |
| 2026-05-27 | Daly James M | Director | Grant | 3K | $0.00 | $0 | 3K |
| 2026-05-27 | Harrington Robert Arthur | Director | Grant | 3K | $0.00 | $0 | 22K |
| 2026-05-27 | HENDERSON JOHN T | Director | Grant | 3K | $0.00 | $0 | 78K |
| 2026-05-27 | Kaye Edward M. MD | Director | Grant | 3K | $0.00 | $0 | 13K |
| 2026-05-27 | PARSHALL B LYNNE | Director | Grant | 3K | $0.00 | $0 | 21K |
| 2026-05-27 | Landry Robert E | Director | Grant | 3K | $0.00 | $0 | 10K |
| 2026-05-27 | WIERENGA WENDELL | Director | Grant | 3K | $0.00 | $0 | 35K |
| 2026-05-27 | Wysenski Nancy | Director | Grant | 3K | $0.00 | $0 | 34K |
| 2026-05-27 | Bhanji Muna | Director | Grant | 3K | $0.00 | $0 | 26K |
| 2026-05-27 | Blum Robert I | President & CEO | Sell | 8K | $77.21 | $579K | 393K |
| 2026-05-19 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $75.69 | $265K | 154K |
| 2026-05-19 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-05-14 | Blum Robert I | President & CEO | Sell | 8K | $77.92 | $584K | 400K |
| 2026-05-05 | Malik Fady Ibraham | EVP Research & Development | Sell | 4K | $77.37 | $271K | 154K |
| 2026-05-05 | Malik Fady Ibraham | EVP Research & Development | Exercise or conversion | 4K | $7.80 | $27K | 157K |
| 2026-05-05 | WIERENGA WENDELL | Director | Sell | 4K | $75.00 | $302K | 33K |
| 2026-05-05 | WIERENGA WENDELL | Director | Exercise or conversion | 4K | $12.40 | $50K | 37K |
| 2026-05-05 | Lee Sung | EVP, Chief Financial Officer | Sell | 24K | $76.87 | $1.8M | 63K |
| 2026-05-05 | HENDERSON JOHN T | Director | Sell | 20K | $75.97 | $1.5M | 75K |
| 2026-05-05 | HENDERSON JOHN T | Director | Exercise or conversion | 20K | $7.61 | $152K | 95K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON34 Form 144 notices on file for CYTK worth $44.3M at the prices reported; 4 in the last 90 days worth $2.9M. Latest: FADY MALIK filed on 2026-10-20 to sell 16,386 shares ($1.0M) from 2026-10-20.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-20 | FADY MALIKOfficer | 16K | $1.0M | 0.012% | 2026-10-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-13 | ROBERT BLUMDirector, Officer | 23K | $1.4M | 0.016% | 2026-10-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-11 | ROBERT LANDRYDirector | 2K | $147K | 0.001% | 2026-09-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-01 | B LYNNE PARSHALLDirector | 5K | $355K | 0.004% | 2026-09-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-30 | ANDREW CALLOSOfficer | 24K | $1.9M | 0.019% | 2026-07-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-07 | FADY MALIKOfficer | 25K | $2.1M | 0.020% | 2026-07-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | ROBERT BLUMDirector, Officer | 53K | $4.5M | 0.042% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | Sung LeeOfficer | 10K | $781K | 0.008% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | Sung LeeOfficer | 7K | $541K | 0.005% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-24 | Sung LeeOfficer | 39K | $3.1M | 0.031% | 2026-06-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | EDWARD KAYEDirector | 3K | $225K | 0.002% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-05 | WENDELL WIERENGADirector | 4K | $266K | 0.003% | 2026-05-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-05 | JOHN HENDERSONDirector | 20K | $1.3M | 0.016% | 2026-05-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-05 | SUNG LEEOfficer | 24K | $1.6M | 0.019% | 2026-05-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-15 | ANDREW CALLOSOfficer | 80K | $5.3M | 0.065% | 2026-04-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-07 | FADY MALIKOfficer | 22K | $1.4M | 0.018% | 2026-04-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-01 | ROBERT BLUMDirector, Officer | 45K | $3.0M | 0.037% | 2026-04-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-31 | ANDREW CALLOSOfficer | 4K | $229K | 0.003% | 2026-03-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-18 | ANDREW CALLOSOfficer | 2K | $120K | 0.002% | 2026-03-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | ANDREW CALLOSOfficer | 2K | $103K | 0.001% | 2026-03-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | B LYNNE PARSHALLDirector | 10K | $622K | 0.008% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-02 | ANDREW CALLOSOfficer | 60K | $3.8M | 0.049% | 2026-01-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-29 | ANDREW CALLOSOfficer | 2K | $114K | 0.001% | 2025-12-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-22 | WENDELL WIERENGADirector | 20K | $1.3M | 0.016% | 2025-12-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-05 | ANDREW CALLOSOfficer | 54K | $3.6M | 0.044% | 2025-12-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-02 | JOHN T HENDERSONDirector | 9K | $578K | 0.007% | 2025-12-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-01 | EDWARD KAYEDirector | 28K | $1.9M | 0.023% | 2025-12-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-19 | B LYNNE PARSHALLDirector | 5K | $331K | 0.004% | 2025-11-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-12 | EDWARD KAYEDirector | 5K | $322K | 0.004% | 2025-11-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-27 | WENDELL WIERENGADirector | 4K | $253K | 0.004% | 2025-10-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-21 | FADY MALIKOfficer | 11K | $653K | 0.009% | 2025-10-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-06 | EDWARD KAYEDirector | 7K | $385K | 0.006% | 2025-10-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-01 | ROBERT BLUMDirector, Officer | 15K | $824K | 0.013% | 2025-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-30 | EDWARD KAYEDirector | 7K | $361K | 0.006% | 2025-09-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of CYTK in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 14.5% of the class (17,716,372 shares), filed 2026-02-17 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 2 | Wellington Management Group LLPparent holding company | 7.1M | 5.1% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 2 | Wellington Group Holdings LLPparent holding company | 7.1M | 5.1% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 2 | Wellington Investment Advisors Holdings LLPparent holding company | 7.1M | 5.1% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 8 | FMR LLCparent holding company | 5.2M | 3.9% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 8 | Abigail P. Johnsonindividual | 5.2M | 3.9% | 2026-06-30 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 6.4M | 5.2% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 11 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 3 | T. Rowe Price Investment Management, Inc.investment adviser | 17.7M | 14.5% | 2025-12-31 |
| 2025-11-10 | 13G | STATE STREET CORPORATIONparent holding company | 5.6M | 4.7% | 2025-09-30 |
13F holders
Tracked managers holding CYTK at their latest 13F. JSON7 of the 30 tracked managers held CYTK at their latest 13F, $392.7M in total at quarter-end prices. Point72 Asset Management is the largest at $135.3M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 1.6M | $135.3M | 0.15% | +962K |
| D. E. Shaw & Co. | 2026-06-30 | 1.0M | $89.3M | 0.04% | +341K |
| Fisher Asset Management | 2026-06-30 | 744K | $63.4M | 0.02% | -25K |
| Citadel Advisors | 2026-06-30 | 641K | $54.6M | 0.01% | -459K |
| Two Sigma Investments | 2026-06-30 | 317K | $27.0M | 0.02% | +32K |
| AQR Capital Management | 2026-06-30 | 162K | $13.8M | 0.00% | +5K |
| Millennium Management | 2026-06-30 | 110K | $9.3M | 0.00% | +12K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Cytokinetics reported revenue of $28.6M, down 57.1% from the same quarter a year earlier, and net loss of $198.8M (-1.50 diluted EPS). In FY 2025 it generated -$510.0M of operating cash flow. As of 2026-06-30, cash was $255.3M against $248.2M of debt.
- Cash
- $255.3M
- Debt
- $248.2M
- Equity
- -$173.5M
- Total assets
- $1.92B
- Shares outstanding
- 139,023,418
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $28.6M | -$198.8M | -694.4% | -1.50 |
| Q1 FY 2026 | 2026-03-31 | $19.4M | -$206.0M | -1064.5% | -1.67 |
| Q4 FY 2025derived | 2025-12-31 | $17.8M | -$183.0M | -1030.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $1.9M | -$306.2M | -15815.0% | -2.55 |
| Q2 FY 2025 | 2025-06-30 | $66.8M | -$134.4M | -201.2% | -1.12 |
| Q1 FY 2025 | 2025-03-31 | $1.6M | -$161.4M | -10220.1% | -1.36 |
| Q4 FY 2024derived | 2024-12-31 | $16.9M | -$150.0M | -886.3% | n/a |
| Q3 FY 2024 | 2024-09-30 | $463K | -$160.5M | -34674.9% | -1.36 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $88.0M | -$785.0M | -$510.0M | $24.8M | n/a | n/a |
| FY 2024 | 2024-12-31 | $18.5M | -$589.5M | -$395.9M | $3.9M | n/a | n/a |
| FY 2023 | 2023-12-31 | $7.5M | -$526.2M | -$414.3M | $1.4M | n/a | n/a |
| FY 2022 | 2022-12-31 | $94.6M | -$389.0M | -$299.5M | $11.3M | n/a | n/a |
| FY 2021 | 2021-12-31 | $70.4M | -$215.3M | -$142.5M | $48.9M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-04 from the cover page.
What this page is
Cytokinetics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Cytokinetics (CYTK), SEC CIK 1061983, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-20.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-20.JSON and CSV
- Company record
- EDGAR filing index for CIK 1061983Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of CYTK is sold short?
18,628,116 shares were held short at the 2026-10-15 settlement, 8.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CYTK's daily short volume?
On 2026-10-28, 297,758 of the 556,201 CYTK shares reported to FINRA were sold short, 53.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CYTK have fails to deliver?
The SEC's latest file shows 2,845 CYTK shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are CYTK insiders buying or selling?
Insiders at CYTK reported 15 open-market sells worth $11.8M in the last 90 days and no open-market buys. Latest filing: Malik Fady Ibraham (EVP Research & Development) on 2026-10-20.
Have CYTK insiders filed to sell?
34 Form 144 notices on file for CYTK worth $44.3M at the prices reported; 4 in the last 90 days worth $2.9M. Latest: FADY MALIK filed on 2026-10-20 to sell 16,386 shares ($1.0M) from 2026-10-20.
Who owns 5% or more of CYTK?
5 holders report 5% or more of CYTK in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 14.5% of the class (17,716,372 shares), filed 2026-02-17 for an event on 2025-12-31.
What did CYTK report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Cytokinetics reported revenue of $28.6M, down 57.1% from the same quarter a year earlier, and net loss of $198.8M (-1.50 diluted EPS). In FY 2025 it generated -$510.0M of operating cash flow. As of 2026-06-30, cash was $255.3M against $248.2M of debt.
Which tracked 13F managers own CYTK?
7 of the 30 tracked 13F managers held CYTK shares at their latest filing, $392.7M in all. The largest: Steve Cohen's Point72 Asset Management (1.6M shares, $135.3M), D. E. Shaw & Co. (1.0M shares, $89.3M), Ken Fisher's Fisher Asset Management (744K shares, $63.4M), Ken Griffin's Citadel Advisors (641K shares, $54.6M), Two Sigma Investments (317K shares, $27.0M), Cliff Asness's AQR Capital Management (162K shares, $13.8M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.